Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a leading biopharmaceutical company with the prime focus on the development and commercialization of innovative therapies to treat debilitating diseases, updates trial results. As per the reports, the company has come up with the top-line trial results of CPP-109 or vigabatrin.
It can be used to treat all those patients who are suffering from TD (Tourette’s Disorder). It’s the first time when any pharmaceutical company has successfully come up with an appropriate solution to treating TD.
Insights On The Trial Results:
Out of all four patients who were given CPP-109, 25% showed a clear reduction in tics while two other unveiled 25% cutback in tics; however, there was no subjective clinical improvement. The senior management of Catalyst Pharmaceuticals is delighted to share the results with all the stakeholders and hopes to improve them in the future. According to Patrick J. McEnany, CEO, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)s, these trials unveil one thing very clearly that no matter how small the subjects are, the results are promising.
These top-line results are encouraging for all those people who are suffering from Tourette’s Disorder. They can not only be treated, but return to their normal lives within a short span of time and get free from all sorts of pains. The mechanism of action of CPP-109 clearly validates CPP-115’s potential to be a preferred candidate for Tourette’s Disorder’s treatment. There are various aspects to look at right now, and Catalyst Pharmaceuticals doesn’t want to leave any stone unturned.
The company is planning to meet the Co-Principal Investigators who played a vital role in carrying out this trial. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) wants to meet every single person associated with this trial to understand their point of view and plan the next phase of development in an effective way. The company promises to share all the future results of trials as soon as it comes up with something important.